Quick Answer
Galera Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $6.38 million for the year ending 2025.
- Galera Therapeutics, Inc. showed a decrease of -23.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Galera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $15.72 million | Q1 2020: $21.58 million | Q2 2020: $15.88 million | Q3 2020: $15.23 million | Q1 2021: $13.69 million | Q2 2021: $38.47 million | Q3 2021: $17.63 million | Q1 2022: $19.65 million | Q2 2022: $17.38 million | Q3 2022: $12.73 million | Q1 2023: $25.69 million | Q2 2023: $24.30 million | Q3 2023: $24.38 million | Q1 2024: $13.47 million | Q2 2024: $10.75 million | Q3 2024: $8.46 million | Q1 2025: $6.69 million | Q2 2025: $5.23 million | Q3 2025: $4.47 million.
- Over the full 8 years of available data (2018 to 2025), Galera Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 57.0%.
- Historical annual values: Fiscal year 2025: $6.38 million | Fiscal year 2024: $8.29 million | Fiscal year 2023: $18.26 million | Fiscal year 2022: $4.27 million | Fiscal year 2021: $19.86 million | Fiscal year 2020: $15.87 million | Fiscal year 2019: $18.36 million | Fiscal year 2018: $14.81 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: